{
    "clinical_study": {
        "@rank": "16549", 
        "arm_group": {
            "arm_group_label": "Group 1"
        }, 
        "brief_summary": {
            "textblock": "The objective of this PMS is to gain information about safety and efficacy in real practice\n      as a regulatory commitment required by KFDA(Korea Food and drug administration)"
        }, 
        "brief_title": "Qlaira rPMS (Regulatory Post Marketing Surveillance) Study in Korea", 
        "completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Contraception", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed and dated informed consent\n\n          -  Women after menarche and before menopause\n\n          -  Women requesting contraception  or Women diagnosed by a physician as having HMB due\n             to non-organic cause who are also requesting contraception\n\n          -  Women who are prescribed Qlaira\u00ae for the first time, during the study period\n\n        Exclusion Criteria:\n\n        - All contraindications according to the local marketing authorization have to be\n        considered."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Generally healthy women after menarche and before menopause desiring contraception with or\n        without HMB will be recruited who are determined to start Qlaira"
            }
        }, 
        "enrollment": {
            "#text": "720", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01797809", 
            "org_study_id": "16344", 
            "secondary_id": "QL1212KR"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "Patients in daily life clinical practice tratment receiving Qlaira  according to indication on the label.", 
            "intervention_name": "EV/DNG (Qlaira, BAY86-5027)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 16, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "Korea, Republic of"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Qlaira\u00ae Regulatory Post Marketing Surveillance Study in Korea", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea : Korea Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of ocular adverse events(AEs) including serious adverse events (SAEs) and Adverse Drug Reactions (ADRs)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 6months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01797809"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Contraceptive Efficacy by Number of unintended pregnancies", 
                "safety_issue": "No", 
                "time_frame": "From 3 to 6 months"
            }, 
            {
                "measure": "Contraceptive Efficacy by Compliance with Qlaira taking : Administered tablet number/prescribed tablet number", 
                "safety_issue": "No", 
                "time_frame": "From 3 to 6 months"
            }, 
            {
                "measure": "The relief of heavy menstrual bleeding symptom also will be calculated as an efficacy variable from admission to the study until final visit by subject's assessment", 
                "safety_issue": "No", 
                "time_frame": "From 3 to 6 months"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}